Fatal pancreatitis occurred in a patient with refractory CD30+ anaplastic large cell lymphoma after brentuximab vedotin treatment
Brentuximab vedotin is a quite safe and effective targeted drug for patients with CD30+ anaplastic large cell lymphoma, but we still need to be careful some rare and severe adverse events after brentuximab vedotin treatment. Here we present a 32-year-old Asian male with CD30+ anaplastic large cell l...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wolters Kluwer Medknow Publications
2017-03-01
|
| סדרה: | Journal of Cancer Research and Practice |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2311300616301264 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|